We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+8.76%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.27B
AUM Growth
+$215M
Cap. Flow
+$13.1M
Cap. Flow %
0.4%
Top 10 Hldgs %
74.79%
Holding
30
New
–
Increased
16
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$19M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$11.9M
4
TSRO
TESARO, Inc.
TSRO
+$7.73M
5
HALO icon
Halozyme
HALO
+$6.88M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$28.4M
2
CELG
Celgene Corp
CELG
+$11M
3
PBYI icon
Puma Biotechnology
PBYI
+$9.14M
4
KITE
Kite Pharma, Inc.
KITE
+$8.16M
5
PTCT icon
PTC Therapeutics
PTCT
+$6.72M

Sector Composition

Rank Sector Weight
1 Healthcare 89.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
26
Novavax
NVAX
$1.31B
$9.58M 0.29%
416,500
– –
CDTX
27
DELISTED
Cidara Therapeutics
CDTX
$8.27M 0.25%
55,129
+2,938
+6% +$406K
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
$5.87M 0.18%
1,279,340
– –
PBYI icon
29
Puma Biotechnology
PBYI
$454M
– –
-245,616
Closed -$9.14M
PTCT icon
30
PTC Therapeutics
PTCT
$6.12B
– –
-682,912
Closed -$6.72M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2017 Portfolio in Review

As of Q2 2017, BB Biotech held 30 positions worth $3.27B, up 7% from $3.06B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

BB Biotech's Q2 2017 filing shows 16 increased, 6 reduced and 2 closed positions. The largest sale was Regeneron Pharmaceuticals, an estimated $28.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier.

  • BB Biotech added most to Radius Health, Inc. in Q2 2017, an estimated $19M increase.
  • BB Biotech's biggest Q2 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $28.4M.
  • BB Biotech fully exited Puma Biotechnology in Q2 2017, selling an estimated $9.14M.
  • BB Biotech's ten largest holdings make up 75% of its $3.27B portfolio in Q2 2017.
  • BB Biotech opened 0 new positions and closed 2 in Q2 2017.
  • BB Biotech's portfolio value rose 7% quarter-over-quarter to $3.27B.

Based on BB Biotech's 13F filing for Q2 2017, filed 11 Aug 2017.